Complications of TM, by age group
. | 0-15 y, % (no. positive/no. tested) . | 16-24 y, % (no. positive/no. tested) . | 25 y and older, % (no. positive/no. tested) . | Overall, % (no. positive/no. tested) . |
|---|---|---|---|---|
| Infectious complications | ||||
| Hepatitis C exposure, Ab+ or RNA+ | 5 (6/115) | 23 (21/91) | 70 (90/128) | 35 (117/334) |
| Chronic hepatitis C, Ab+ and RNA+* | 100 (3/3) | 56 (9/16) | 66 (37/56) | 65 (49/75) |
| Spontaneous clearance, Ab+ and RNA-† | 0 (0/3) | 43 (6/14) | 32 (14/44) | 33 (20/61) |
| Heart disease requiring medication | 0 (0/120) | 5 (5/93) | 23 (30/128) | 10 (35/341) |
| Cirrhosis by biopsy | 4 (3/70) | 10 (6/62) | 15 (15/100) | 10 (24/232) |
| Liver failure/cirrhosis by clinical findings | 0 (0/119) | 5 (5/93) | 6 (8/125) | 4 (13/337) |
| Endocrine disorders | ||||
| Thyroid disease | 0 | 8 | 17 | 9 |
| Hypoparathyroidism | 0 | 1 | 9 | 4 |
| Diabetes mellitus | 0 | 9 | 21 | 10 |
| Hypogonadism requiring medications | 0 | 41 | 62 | 35 |
| More than 0 endocrinopathies | 0 | 45 | 67 | 38 |
| More than 1 endocrinopathy | 0 | 10 | 27 | 13 |
| More than 2 endocrinopathies | 0 | 3 | 12 | 6 |
| More than 3 endocrinopathies | 0 | 0 | 2 | 1 |
. | 0-15 y, % (no. positive/no. tested) . | 16-24 y, % (no. positive/no. tested) . | 25 y and older, % (no. positive/no. tested) . | Overall, % (no. positive/no. tested) . |
|---|---|---|---|---|
| Infectious complications | ||||
| Hepatitis C exposure, Ab+ or RNA+ | 5 (6/115) | 23 (21/91) | 70 (90/128) | 35 (117/334) |
| Chronic hepatitis C, Ab+ and RNA+* | 100 (3/3) | 56 (9/16) | 66 (37/56) | 65 (49/75) |
| Spontaneous clearance, Ab+ and RNA-† | 0 (0/3) | 43 (6/14) | 32 (14/44) | 33 (20/61) |
| Heart disease requiring medication | 0 (0/120) | 5 (5/93) | 23 (30/128) | 10 (35/341) |
| Cirrhosis by biopsy | 4 (3/70) | 10 (6/62) | 15 (15/100) | 10 (24/232) |
| Liver failure/cirrhosis by clinical findings | 0 (0/119) | 5 (5/93) | 6 (8/125) | 4 (13/337) |
| Endocrine disorders | ||||
| Thyroid disease | 0 | 8 | 17 | 9 |
| Hypoparathyroidism | 0 | 1 | 9 | 4 |
| Diabetes mellitus | 0 | 9 | 21 | 10 |
| Hypogonadism requiring medications | 0 | 41 | 62 | 35 |
| More than 0 endocrinopathies | 0 | 45 | 67 | 38 |
| More than 1 endocrinopathy | 0 | 10 | 27 | 13 |
| More than 2 endocrinopathies | 0 | 3 | 12 | 6 |
| More than 3 endocrinopathies | 0 | 0 | 2 | 1 |
In this cross-sectional methodology, not every patient is screened for every test. Evidence of hepatitis C by liver biopsy was not queried by the database.
For the endocrine disorders, the numbers of patients in each age group and overall were 120, 93, 129, and 342, respectively.
These results are of the patients (n = 75) with a positive test for anti-HCV antibodies and a concurrent or subsequent HCV RNA assay.
These results are of the patients (n = 61) with a positive test for anti-HCV antibodies and a concurrent or subsequent HCV RNA assay who have never been treated for hepatitis C.